PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Personalized cellular therapy achieves complete remission in 90 percent of acute lymphoblastic leukemia patients studied

University of Pennsylvania and Children's Hospital of Philadelphia studies reveal unprecedented results with investigational therapy made from patients' own immune cells

2014-10-16
(Press-News.org) PHILADELPHIA – Ninety percent of children and adults with acute lymphoblastic leukemia (ALL) who had relapsed multiple times or failed to respond to standard therapies went into remission after receiving an investigational personalized cellular therapy, CTL019, developed at the Perelman School of Medicine at the University of Pennsylvania. The results are published this week in The New England Journal of Medicine.

The new data, which builds on preliminary findings presented at the American Society of Hematology's annual meeting in December 2013, include results from the first 25 children and young adults (ages 5 to 22) treated at the Children's Hospital of Philadelphia and first five adults (ages 26 to 60) treated at the Hospital of the University of Pennsylvania. Twenty-seven of the 30 patients in the studies achieved a complete remission after receiving an infusion of these engineered "hunter" cells, and 78 percent of the patients were alive six months after treatment.

"The patients who participated in these trials had relapsed as many as four times, including 60 percent whose cancers came back even after stem cell transplants. Their cancers were so aggressive they had no treatment options left," said the study's senior author, Stephan Grupp, MD, PhD, a professor of Pediatrics in Penn's Perelman School of Medicine and director of Translational Research in the Center for Childhood Cancer Research at the Children's Hospital of Philadelphia. "The durable responses we have observed with CTL019 therapy are unprecedented."

Shannon Maude, MD, PhD, an assistant professor of Pediatrics and a pediatric oncologist at CHOP, and Noelle Frey, MD, MSCE, an assistant professor of Medicine and an oncologist at Penn's Abramson's Cancer Center, are co-first authors of the new study. The research team is led by Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine and director of Translational Research in the Abramson Cancer Center, along with David Porter, MD, the Jodi Fisher Horowitz Professor in Leukemia Care Excellence and director of Blood and Marrow Transplantation in the Abramson Cancer Center.

CTL019 manufacturing begins with a patient's own T cells, which are collected via an apheresis process similar to blood donation, then reprogrammed in Penn's Clinical Cell and Vaccine Production Facility with a gene transfer technique that teaches the T cells to target and kill tumor cells. The engineered cells contain an antibody-like protein known as a chimeric antigen receptor (CAR), which is designed to bind to a protein called CD19 found on the surface of B cells, including the cancerous B cells that characterize several types of leukemia. The modified "hunter" cells are then infused back into the patient's body, where they both multiply and attack the cancer cells. A signaling domain built into the CAR promotes rapid multiplication of the "hunter" cells, building an army of tumor-killing cells that tests reveal can grow to more than 10,000 new cells for each single engineered cell patients receive.

Nineteen patients in the study remain in remission, 15 with this therapy alone, including a 9 year old who was the first ALL patient to receive the therapy more than two years ago. The follow-up periods reported in the study are more than six months for most patients, with a range from 1.4 to 24 months. Five patients went off-study for alternate therapy, three of whom proceeded to allogeneic stem cell transplants while in remission. Seven patients relapsed, between 6 weeks and 8.5 months after their infusions, including three whose cancers returned as CD19-negative leukemia that would not have been targeted by the modified cells.

All patients who received the CTL019 "hunter" cells experienced a cytokine release syndrome (CRS) within a few days after receiving their infusions – a key indicator that the engineered cells have begun proliferating and killing tumor cells in the body. During this time, 22 of 30 patients experienced mild to moderate CRS, which included varying degrees of flu-like symptoms, with high fevers, nausea, and muscle pain. Eight patients developed severe CRS, which required treatment for low blood pressure and breathing difficulties. Nine patients were treated with tocilizumab, an immunosuppressant drug that blocks the effects of the inflammatory cytokine IL-6, which have been found to spike during the most robust phase of the engineered cells' expansion in the body. Six patients also received short courses of steroids to combat CRS symptoms. All patients on these studies fully recovered from the CRS.

Tests of all patients who experienced complete remissions also showed that their normal, non-cancerous B cells, which also express the CD19 protein, had been eliminated along with their tumors. The researchers note that persistent absence of normal B cells following CTL019 treatment indicates continued activity of the gene-modified T cells, which are thought to provide long-term, vaccine-like activity preventing tumor recurrence. Since B cells play a role in helping fight infection, patients typically receive immunoglobulin replacement to maintain healthy immune function.

"Our results support that CTL019 can produce long-lasting remissions for certain heavily pre-treated ALL patients without further therapy," Frey said. "For our patients who have already relapsed after stem cell transplants, or don't have any options for donors, this option has provided new hope."

In July 2014, the U.S. Food and Drug Administration granted CTL019 its Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric ALL, a step which is intended to expedite the development and review of new medicines that treat serious or life-threatening conditions, if a therapy has demonstrated substantial advantages over available treatments. CTL019 is the first personalized cellular therapy to receive the designation. The first multicenter CTL019 trial has recently opened in the U.S., and additional multisite trials are expected to initiate by the end of the year.

INFORMATION:

The study was supported by the National Institutes of Health (1R01CA165206, R01CA102646 and R01CA116660), The Leukemia and Lymphoma Society, and a Stand Up To Cancer-St. Baldrick's Pediatric Dream Team Translational Research Grant.

Editor's note: The University of Pennsylvania has licensed technologies involved in this trial to Novartis. Some of the scientists involved in these trials are inventors of these technologies, including Drs. June, Porter, and Grupp. As a result of the licensing relationship with Novartis, the University of Pennsylvania and the Children's Hospital of Philadelphia receive significant financial benefit, and the inventors have benefitted financially and/or may benefit financially in the future.

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise. The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year. The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine. Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community. About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program receives the highest amount of National Institutes of Health funding among all U.S. children's hospitals. In addition, its unique family-centered care and public service programs have brought the 535-bed hospital recognition as a leading advocate for children and adolescents. The Children's Hospital of Philadelphia has one of the largest pediatric cancer programs in the United States, which has been top ranked by U.S.News & World Report and Parents Magazine. Its large basic and clinical research programs are particularly strong in pediatric neuro-oncology, neuroblastoma, leukemia and lymphoma, and sarcomas. Of all pediatric institutions, Children's Hospital enrolls the most patients in national clinical trials, working in close collaboration with national organizations such as the Children's Oncology Group. Physicians at Children's Hospital have had pioneering roles in developing international standards for diagnosing and treating neuroblastoma, and in developing programs for survivors of childhood cancer. For more information, visit http://www.chop.edu/cancer.



ELSE PRESS RELEASES FROM THIS DATE:

Diversity in medical education: It's not so black and white anymore

2014-10-16
PHILADELPHIA—A perspective piece in this week's issue of the New England Journal of Medicine from a student at the University of Pennsylvania's Perelman School of Medicine addresses the evolution of diversity in medical education. "It's not a numbers game anymore," says author Mark A. Attiah, a medical student pursuing both a Master's in translational research and bioethics. "Diversity is a mindset that extends into the classroom and the hospital." Achieving diversity in today's medical schools goes beyond bringing underrepresented students into the fold, he says. ...

Weight gain study suggests polyunsaturated oil healthier option

2014-10-15
Short-term modest weight gains in healthy, normal weight young adults was associated with more bad cholesterol levels in those who ate muffins cooked using saturated oil. However, individuals in the same study who ate muffins made with polyunsaturated oils had improved blood cholesterol profiles, according to a new study published in the Journal of the American Heart Association. Swedish researchers conducted a seven-week study in 39 adults (average age 27) who added three muffins each day made with either unsaturated sunflower or saturated palm oil. The study was designed ...

Leisure time physical activity linked to lower depression risk

2014-10-15
Being physically active three times a week reduces the odds of being depressed by approximately 16%, according to new UCL (University College London) research undertaken as part of the Public Health Research Consortium. The study, published in JAMA Psychiatry, found a two-way relationship between depression and physical activity. People who increased their weekly activity reported fewer depressive symptoms but those with more depressive symptoms were less active, particularly at younger ages. Researchers followed 11,135 people born in 1958 up until the age of 50, recording ...

Penn Medicine researchers zero in on psoriasis-hypertension link

2014-10-15
PHILADELPHIA – Patients with more severe psoriasis are also more likely to have uncontrolled hypertension, according to new research by a team at the Perelman School of Medicine at the University of Pennsylvania. Through a cross-sectional study using information collected from a medical records database, the results provide further evidence of a strong link between psoriasis and hypertension. Full results are now available in JAMA Dermatology. "Over the last several years, studies have shown that psoriasis, specifically severe psoriasis, is an independent risk factor ...

Fewer depressive symptoms associated with more frequent activity in adults at most ages

2014-10-15
Bottom Line: On average, more frequent physical activity was associated with fewer depressive symptoms for adults between the ages of 23 and 50 years, while a higher level of depressive symptoms was linked to less frequent physical activity. Authors: Snehal M. Pinto Pereira, Ph.D., of the University College London, England, and colleagues. Background: Physical activity can reduce the risk of death, stroke and some cancers, and some studies suggest activity can also lower the risk for depressive symptoms. But the evidence on activity and depression has limitations. ...

Uncontrolled hypertension highest among patients with moderate-to-severe psoriasis

2014-10-15
Bottom Line: Patients with moderate and severe psoriasis have the greatest likelihood of uncontrolled hypertension compared to patients without psoriasis. Author: Junko Takeshita, M.D., Ph.D., of the University of Pennsylvania Perelman School of Medicine, Philadelphia, and colleagues. Background: Psoriasis is a chronic inflammatory disease of the skin and cardiovascular risk factors, including hypertension, are more prevalent among patients with psoriasis compared to those patients without. Previous studies suggest that psoriasis, especially when it is more severe, ...

MD Anderson study first to compare treatments, survival benefits for early-stage lung cancer

2014-10-15
Removal of the entire lobe of lung may offer patients with early-stage lung cancer better overall survival when compared with a partial resection, and stereotactic ablative radiotherapy (SABR) may offer the same survival benefit as a lobectomy for some patients, according to a study from The University of Texas MD Anderson Cancer Center. The research is the largest population-based study to review modern treatment modalities for early-stage lung cancer and is published in JAMA Surgery. According to the American Cancer Society, in 2014, 224,210 people in the U.S. are ...

Reminding people of their religious belief system reduces hostility: York U research

2014-10-15
TORONTO, Oct 15, 2014 – Few topics can prove more divisive than religion, with some insisting it promotes compassion, selflessness and generosity, and others arguing that it leads to intolerance, isolation and even violence. New research conducted at York University, published in the Journal of Personality and Social Psychology, may shed some light on religion's actual influence on believers – and the news is positive. "Based on our premise that most people's religious beliefs are non-hostile and magnanimous, we hypothesized that being reminded of religious ...

How closely do urologists adhere to AUA guidelines?

2014-10-15
New York, NY, October 16, 2014 – Evidence-based guidelines play an increasing role in setting standards for medical practice and quality but are seldom systematically evaluated in the practice setting. Investigators evaluated the rate of physician adherence to the American Urological Association's (AUA) guidelines on the management of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) to establish a benchmark for future research. Their findings are published in The Journal of Urology®. Medical certification bodies, for example, the American ...

NASA's Aqua satellite watches Tropical Storm Ana intensifying

NASAs Aqua satellite watches Tropical Storm Ana intensifying
2014-10-15
NASA's Aqua satellite passed over intensifying Tropical Storm Ana as it was moving through the Central Pacific Ocean and toward the Hawaiian Islands. On Oct. 14 at 22:50 UTC (6:50 p.m. EDT) the MODIS instrument aboard NASA's Aqua satellite captured a visible image of Tropical Storm Ana in the Central Pacific Ocean. The MODIS image showed a tight concentration of thunderstorms surrounding the center of Ana's circulation. At 1500 UTC (11 a.m. EDT/5 a.m. HST) on Wed. Oct. 15, Tropical Storm Ana's maximum sustained winds were near 70 mph (110 kph). Ana is forecast to gradually ...

LAST 30 PRESS RELEASES:

Pink skies

Monkeys are world’s best yodellers - new research

Key differences between visual- and memory-led Alzheimer’s discovered

% weight loss targets in obesity management – is this the wrong objective?

An app can change how you see yourself at work

NYC speed cameras take six months to change driver behavior, effects vary by neighborhood, new study reveals

New research shows that propaganda is on the rise in China

Even the richest Americans face shorter lifespans than their European counterparts, study finds

Novel genes linked to rare childhood diarrhea

New computer model reveals how Bronze Age Scandinavians could have crossed the sea

Novel point-of-care technology delivers accurate HIV results in minutes

Researchers reveal key brain differences to explain why Ritalin helps improve focus in some more than others

Study finds nearly five-fold increase in hospitalizations for common cause of stroke

Study reveals how alcohol abuse damages cognition

Medicinal cannabis is linked to long-term benefits in health-related quality of life

Microplastics detected in cat placentas and fetuses during early pregnancy

Ancient amphibians as big as alligators died in mass mortality event in Triassic Wyoming

Scientists uncover the first clear evidence of air sacs in the fossilized bones of alvarezsaurian dinosaurs: the "hollow bones" which help modern day birds to fly

Alcohol makes male flies sexy

TB patients globally often incur "catastrophic costs" of up to $11,329 USD, despite many countries offering free treatment, with predominant drivers of cost being hospitalization and loss of income

Study links teen girls’ screen time to sleep disruptions and depression

Scientists unveil starfish-inspired wearable tech for heart monitoring

Footprints reveal prehistoric Scottish lagoons were stomping grounds for giant Jurassic dinosaurs

AI effectively predicts dementia risk in American Indian/Alaska Native elders

First guideline on newborn screening for cystic fibrosis calls for changes in practice to improve outcomes

Existing international law can help secure peace and security in outer space, study shows

Pinning down the process of West Nile virus transmission

UTA-backed research tackles health challenges across ages

In pancreatic cancer, a race against time

Targeting FGFR2 may prevent or delay some KRAS-mutated pancreatic cancers

[Press-News.org] Personalized cellular therapy achieves complete remission in 90 percent of acute lymphoblastic leukemia patients studied
University of Pennsylvania and Children's Hospital of Philadelphia studies reveal unprecedented results with investigational therapy made from patients' own immune cells